Gita Suneja, MD
The HIV status of a patient who is living with the infection and has been diagnosed with cancer may be a component of a diagnostic workup but should not be the sole determining factor in making decisions about treatment, according to the first set of National Comprehensive Cancer Network (NCCN) guidelines for this population.1
A consult with both an oncologist and an HIV pharmacist before initiating cancer therapy is recommended because of the possibility of drug– drug interactions, and co-management is critical. Suneja also noted that testing for CD4 T-cell count and viral load should be done more frequently to prevent potential interactions that could make ART less effective.
... to read the full story